Our Company

Ikaria is a biotherapeutics company whose acute care therapies address the significant unmet needs of critically ill patients. Our deep understanding of the biology of critical conditions, insight into the clinical picture of critically ill patients, and our working knowledge of the needs of critical care providers fuel our efforts. We strive to provide the advanced therapies and clinical support caregivers need to intervene in the most urgent situations.

We are passionate about science

At Ikaria, advancing critical care science is crucial. Our scientists are devoted to the study of the pathogenetic mechanisms and experimental therapy of critical illness, and they continually test new ideas that will hopefully address areas of significant unmet needs.

We revel in the possibilities

Mark Roth, PhD

Mark Roth, PhD, founding Ikaria scientist and cell biologist at the Fred Hutchinson Cancer Research Center, believes anything is possible, including suspended animation and reanimation—the ability to control metabolic activity. Work in this area could mean buying precious time for critical care patients. We are currently exploring the therapeutic possibilities of this exciting new concept.